S&P 500   3,692.06 (+0.69%)
DOW   30,156.31 (+0.62%)
QQQ   305.17 (+0.29%)
AAPL   122.12 (-0.67%)
MSFT   213.64 (-0.28%)
FB   280.78 (-0.38%)
GOOGL   1,822.03 (+0.01%)
AMZN   3,164.33 (-0.70%)
TSLA   595.87 (+0.42%)
NVDA   539.80 (+0.74%)
BABA   266.55 (-0.13%)
CGC   28.71 (+0.28%)
GE   10.86 (+2.45%)
MU   73.36 (+4.95%)
AMD   94.16 (+2.00%)
T   29.53 (+1.03%)
NIO   43.36 (-4.39%)
F   9.35 (+1.52%)
ACB   11.03 (-1.87%)
BA   232.90 (-1.81%)
NFLX   499.88 (+0.47%)
GILD   61.44 (+0.95%)
DIS   153.95 (+0.46%)
S&P 500   3,692.06 (+0.69%)
DOW   30,156.31 (+0.62%)
QQQ   305.17 (+0.29%)
AAPL   122.12 (-0.67%)
MSFT   213.64 (-0.28%)
FB   280.78 (-0.38%)
GOOGL   1,822.03 (+0.01%)
AMZN   3,164.33 (-0.70%)
TSLA   595.87 (+0.42%)
NVDA   539.80 (+0.74%)
BABA   266.55 (-0.13%)
CGC   28.71 (+0.28%)
GE   10.86 (+2.45%)
MU   73.36 (+4.95%)
AMD   94.16 (+2.00%)
T   29.53 (+1.03%)
NIO   43.36 (-4.39%)
F   9.35 (+1.52%)
ACB   11.03 (-1.87%)
BA   232.90 (-1.81%)
NFLX   499.88 (+0.47%)
GILD   61.44 (+0.95%)
DIS   153.95 (+0.46%)
S&P 500   3,692.06 (+0.69%)
DOW   30,156.31 (+0.62%)
QQQ   305.17 (+0.29%)
AAPL   122.12 (-0.67%)
MSFT   213.64 (-0.28%)
FB   280.78 (-0.38%)
GOOGL   1,822.03 (+0.01%)
AMZN   3,164.33 (-0.70%)
TSLA   595.87 (+0.42%)
NVDA   539.80 (+0.74%)
BABA   266.55 (-0.13%)
CGC   28.71 (+0.28%)
GE   10.86 (+2.45%)
MU   73.36 (+4.95%)
AMD   94.16 (+2.00%)
T   29.53 (+1.03%)
NIO   43.36 (-4.39%)
F   9.35 (+1.52%)
ACB   11.03 (-1.87%)
BA   232.90 (-1.81%)
NFLX   499.88 (+0.47%)
GILD   61.44 (+0.95%)
DIS   153.95 (+0.46%)
S&P 500   3,692.06 (+0.69%)
DOW   30,156.31 (+0.62%)
QQQ   305.17 (+0.29%)
AAPL   122.12 (-0.67%)
MSFT   213.64 (-0.28%)
FB   280.78 (-0.38%)
GOOGL   1,822.03 (+0.01%)
AMZN   3,164.33 (-0.70%)
TSLA   595.87 (+0.42%)
NVDA   539.80 (+0.74%)
BABA   266.55 (-0.13%)
CGC   28.71 (+0.28%)
GE   10.86 (+2.45%)
MU   73.36 (+4.95%)
AMD   94.16 (+2.00%)
T   29.53 (+1.03%)
NIO   43.36 (-4.39%)
F   9.35 (+1.52%)
ACB   11.03 (-1.87%)
BA   232.90 (-1.81%)
NFLX   499.88 (+0.47%)
GILD   61.44 (+0.95%)
DIS   153.95 (+0.46%)
Log in
NYSE:WST

West Pharmaceutical Services Stock Forecast, Price & News

$272.06
-0.18 (-0.07 %)
(As of 12/4/2020 02:45 PM ET)
Add
Compare
Today's Range
$270.89
Now: $272.06
$273.92
50-Day Range
$267.71
MA: $282.88
$295.80
52-Week Range
$124.53
Now: $272.06
$305.00
Volume5,207 shs
Average Volume584,251 shs
Market Capitalization$20.11 billion
P/E Ratio71.78
Dividend Yield0.25%
Beta1.13
West Pharmaceutical Services, Inc. manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the United States, Germany, Ireland, France, Other European countries, and internationally. The company operates through two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, and washing and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of components and devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. This segment serves pharmaceutical, diagnostic, and medical device companies. It distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. The company was founded in 1923 and is headquartered in Exton, Pennsylvania.
West Pharmaceutical Services logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.3Community Rank: 2.0Dividend Strength: 3.3Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.12 out of 5 stars


Industry, Sector and Symbol

Industry Fabricated rubber products, not elsewhere classified
Sub-IndustryHealth Care Supplies
SectorMedical
CUSIP95530610
Phone610-594-2900
Employees8,200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.84 billion
Cash Flow$4.47 per share
Book Value$21.26 per share

Profitability

Net Income$241.70 million

Miscellaneous

Market Cap$20.11 billion
Next Earnings Date2/11/2021 (Estimated)
OptionableOptionable
$272.06
-0.18 (-0.07 %)
(As of 12/4/2020 02:45 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive WST News and Ratings via Email

Sign-up to receive the latest news and ratings for WST and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











West Pharmaceutical Services (NYSE:WST) Frequently Asked Questions

How has West Pharmaceutical Services' stock been impacted by Coronavirus?

West Pharmaceutical Services' stock was trading at $147.83 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, WST stock has increased by 84.0% and is now trading at $272.06.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of West Pharmaceutical Services?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for West Pharmaceutical Services in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for West Pharmaceutical Services
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than West Pharmaceutical Services?

Wall Street analysts have given West Pharmaceutical Services a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but West Pharmaceutical Services wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is West Pharmaceutical Services' next earnings date?

West Pharmaceutical Services is scheduled to release its next quarterly earnings announcement on Thursday, February 11th 2021.
View our earnings forecast for West Pharmaceutical Services
.

How were West Pharmaceutical Services' earnings last quarter?

West Pharmaceutical Services, Inc. (NYSE:WST) issued its quarterly earnings results on Thursday, October, 22nd. The medical instruments supplier reported $1.15 earnings per share for the quarter, beating the consensus estimate of $0.99 by $0.16. The medical instruments supplier had revenue of $548 million for the quarter, compared to analysts' expectations of $510.15 million. West Pharmaceutical Services had a return on equity of 19.01% and a net margin of 14.69%. The company's revenue for the quarter was up 20.2% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.79 EPS.
View West Pharmaceutical Services' earnings history
.

How often does West Pharmaceutical Services pay dividends? What is the dividend yield for West Pharmaceutical Services?

West Pharmaceutical Services announced a quarterly dividend on Thursday, October 29th. Shareholders of record on Wednesday, November 11th will be paid a dividend of $0.17 per share on Wednesday, November 18th. This represents a $0.68 annualized dividend and a dividend yield of 0.25%. The ex-dividend date of this dividend is Monday, November 9th. This is a positive change from West Pharmaceutical Services's previous quarterly dividend of $0.16.
View West Pharmaceutical Services' dividend history
.

What guidance has West Pharmaceutical Services issued on next quarter's earnings?

West Pharmaceutical Services issued an update on its FY20 earnings guidance on Thursday, October, 22nd. The company provided earnings per share (EPS) guidance of $4.50-$4.55 for the period, compared to the Thomson Reuters consensus estimate of $3.40. The company issued revenue guidance of $2.10-$2.11 billion, compared to the consensus revenue estimate of $2.05 billion.

What price target have analysts set for WST?

3 Wall Street analysts have issued 12-month target prices for West Pharmaceutical Services' stock. Their forecasts range from $280.00 to $350.00. On average, they expect West Pharmaceutical Services' stock price to reach $310.00 in the next year. This suggests a possible upside of 13.9% from the stock's current price.
View analysts' price targets for West Pharmaceutical Services
.

Are investors shorting West Pharmaceutical Services?

West Pharmaceutical Services saw a decrease in short interest in the month of October. As of October 30th, there was short interest totaling 626,900 shares, a decrease of 17.3% from the October 15th total of 758,000 shares. Based on an average trading volume of 459,700 shares, the short-interest ratio is presently 1.4 days. Approximately 0.9% of the shares of the company are short sold.
View West Pharmaceutical Services' Short Interest
.

Who are some of West Pharmaceutical Services' key competitors?

What other stocks do shareholders of West Pharmaceutical Services own?

Based on aggregate information from My MarketBeat watchlists, some companies that other West Pharmaceutical Services investors own include NVIDIA (NVDA), Johnson & Johnson (JNJ), AbbVie (ABBV), The Walt Disney (DIS), The Home Depot (HD), Visa (V), Alibaba Group (BABA), McDonald's (MCD), Netflix (NFLX) and PepsiCo (PEP).

Who are West Pharmaceutical Services' key executives?

West Pharmaceutical Services' management team includes the following people:
  • Mr. Eric M. Green, Pres, CEO & Director (Age 50, Pay $2.28M)
  • Mr. Bernard J. Birkett, Sr. VP & CFO (Age 51, Pay $1.18M)
  • Mr. David A. Montecalvo, Sr. VP and Chief Operations & Supply Chain Officer (Age 55, Pay $801.65k)
  • Mr. George Lloyd Miller, Sr. VP, Gen. Counsel & Corp. Sec. (Age 65, Pay $835.13k)
  • Mr. Silji Abraham, Chief Digital & Transformation Officer and Sr. VP (Age 48, Pay $796.49k)
  • Mr. Chad R. Winters, VP, Chief Accounting Officer, Principal Accounting Officer & Corp. Controller (Age 42)
  • Mr. Eric Resnick, CTO & VP (Age 56)
  • Dr. Quintin J. Lai C.F.A., Ph.D., VP of Corp. Devel., Strategy & Investor Relations (Age 53)
  • Ms. Annette F. Favorite, Chief HR Officer & Sr. VP (Age 55)
  • Mr. Richard D. Luzzi, Sr. VP of HR (Age 68)

What is West Pharmaceutical Services' stock symbol?

West Pharmaceutical Services trades on the New York Stock Exchange (NYSE) under the ticker symbol "WST."

Who are West Pharmaceutical Services' major shareholders?

West Pharmaceutical Services' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (9.39%), State Street Corp (4.71%), Neuberger Berman Group LLC (2.60%), WCM Investment Management LLC (1.86%), Durable Capital Partners LP (1.50%) and Nuveen Asset Management LLC (1.01%). Company insiders that own West Pharmaceutical Services stock include Annette F Favorite, Daniel Malone, David A Montecalvo, George Lloyd Miller, Patrick J Zenner and Silji Abraham.
View institutional ownership trends for West Pharmaceutical Services
.

Which institutional investors are selling West Pharmaceutical Services stock?

WST stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Wells Fargo & Company MN, WCM Investment Management LLC, Charles Schwab Investment Management Inc., GW&K Investment Management LLC, Durable Capital Partners LP, AJO LP, and Fisher Asset Management LLC. Company insiders that have sold West Pharmaceutical Services company stock in the last year include Annette F Favorite, David A Montecalvo, George Lloyd Miller, Patrick J Zenner, and Silji Abraham.
View insider buying and selling activity for West Pharmaceutical Services
.

Which institutional investors are buying West Pharmaceutical Services stock?

WST stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Massachusetts Financial Services Co. MA, Arrowstreet Capital Limited Partnership, Teacher Retirement System of Texas, Morgan Stanley, Epoch Investment Partners Inc., TD Asset Management Inc., and KBC Group NV.
View insider buying and selling activity for West Pharmaceutical Services
.

How do I buy shares of West Pharmaceutical Services?

Shares of WST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is West Pharmaceutical Services' stock price today?

One share of WST stock can currently be purchased for approximately $272.06.

How big of a company is West Pharmaceutical Services?

West Pharmaceutical Services has a market capitalization of $20.11 billion and generates $1.84 billion in revenue each year. The medical instruments supplier earns $241.70 million in net income (profit) each year or $3.24 on an earnings per share basis. West Pharmaceutical Services employs 8,200 workers across the globe.

What is West Pharmaceutical Services' official website?

The official website for West Pharmaceutical Services is www.westpharma.com.

How can I contact West Pharmaceutical Services?

West Pharmaceutical Services' mailing address is 530 HERMAN O. WEST DRIVE, EXTON PA, 19341. The medical instruments supplier can be reached via phone at 610-594-2900 or via email at [email protected]

This page was last updated on 12/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.